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ABSTRACT
The dystrophin gene has been localised to Xp 21.1. Mutations of this
gene can lead to the clinical manifestations of Duchenne and Becker
muscular dystrophies (DMD/BMD). In the majority of DMD and BMD
patients the disease-causing mutation is a deletion detectable by
southern analysis or multiplex PCB, however in 30% of patients no
deletion is observed using these conventional tests. Using PCR
amplification of eDNA it was possible to detect a deletion in the
product of the dystrophin gene of one such individual affected with
BMD. It was then necessary to characterise the mutation in order to
determine whether this was the disease-causing mutation. The
mutation was found to be a point mutation by genomic sequencing at
the donor splice site consensus sequence of intron 19. This resulted in
alternate splicing of exon 19, two mANA transcripts being produced
one with exon 19 and the other without. This was determined sufficient
to cause BMD in the family. It was then necessary to provide an easy
and efficient diagnostic test in order to determine the carrier status of
females and also to provide those females determined to be carriers
with an accurate prenatal diagnostic test. A new technique, single
strand conformation polymorphism, performed on genomic DNA
provided evidence of conformational difference between the affected
allele and the normal allele. Allele specific primers were also
designed and optimised. These primers, 19FA and 19FC, only varied
at one base, one being the "normal" allele primer and the other the
"affected" allele primer. The amplified product using primers for the
normal and the affected allele were then run on agarose gels and

iii

stained with ethidium bromide providing a quick and easy method of
determining the carrier, affected or normal status of all family
members.
The localisation and characterisation of this splice site mutation
involved many molecular techniques including, RNA extraction, eDNA
synthesis,

nested amplification,

sequencing, single strand

conformation polymorphism and the amplification refractory mutation
system. All of these techniques can be used to isolate and
characterise point or minor mutations in the 30% of

Western

Australian dystrophic families, who currently lack an accurate
diagnostic test lor their dystrophic condition.
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Chapter 1:
1.1

INTRODUCTION

General introduction

Mutations in the dystrophin gene can result not only in Duchenne
muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) but
also familial X-linked myalgia and cramps, which is a non progressive
myopathy associated with a deletion in the dystrophin gene (Gaspe et
al, 1989; Hodgson et al, 1989; Prior et al, 1990). DMD and BIViJ are
progressively degenerative diseases which show a great deal of
variation in both genetic and protein structure. These variations along
1

with other as yet unknown factors, determine the speed at which the
disease progresses (Koenig et al, 1989).
1.2

Duchenne and Becker muscular dystrophy

Duchenne muscular dystrophy and Becker muscular dystrophy are
allelic disorders caused by mutations of the dystrophin gene (Koenig
et al, 1989). DMD, the more severe of these dystrophinopathies,
occurs in approximately 1 in 3500 male births (Hodgson et al, 1989).
BMD, the milder allelic disorder, has a. much lower incidence of
approximately 1 in 30 000 males (Koenig et al, 1989; Prior et al, 1990).
The ipcidence of BMD may prove to be much hig_her now that

•

complementary deoxyribonucleic acid (eDNA) probes have been used
c

to reclassify many limb-girdle muscular dystrophy and spinal muscular
atrophy patients as having BMD (Norman et al; 1989; Patel et al,

1989).
The phenotypes of affected boys have been sub-classified into 3
groups based on the age at which ambulation was lost. Group 1 boys
have DMD and are wheelchair bound by age 13. Group 2 boys form
1

an intermediate group and are wheelchair bound between the ages of
13 and 16. Group 3 boys have BMD and become wheelchair bound
after the age of 16 or may never lose ambulation (Hodgson et al, 1989;
Prior et al, 1990).
Duchenne and Becker muscular dystrophies are X-linked recessive
disorders. X-linked recessive disorders generally only affect males and
are passed througil carrier women. Carrier women are usually
unaffected since the mutated gene is compensated for by the normal
gene on their other X chromosome. All daughters of affected men are
carriers, and the disease is never transmitted from father to son (see
, Figure 1.1) (Gelehrter & Collins, 1990, p. 41 ).

1 .3

Dystrophin gene

The discovery of the dystrophin gene by Kunkel and his co-workers,
(1986) has resulted in a substantial increase in research into both the
structure and function of the dystrophin gene (Hoffman et al, 1987;
Beggs et al, 1990). The dystrophin gene was first sub-localised on the
X chromosome by cytogenetic analysis of several DMD patients with
deletions and translocations of the X chromosome (Francke et al,
1985;. Boyd et al, 1986; Beggs et al, 1990). These cytogenetic
analy§es demonstrated abnormalities in the middle of t~e short arm of

•
.the X chromosome (Xp 21 ). The localisation was then confirmed by
linkage analysis, using polymorphic markers on the short arm of the X
chromosome. These markers were inherited with the disease causing
mutation more than 50% of the time, as would be expected with linked
markers (Laing, 1993). Once the gene that resulted in DMD was
isolated it was then possible to use genomic deoxyribonucleic acid

2

Figure 1.1

X-linked recessive inheritance as in Duchenne/Becker
muscular dystrophies. This pedigree shows how the
probability of inheriting an X-linked gene is 0.5. Males
because of their XY hemizygous condition, have a 50%
ghance of being affected by an X-linked disorder. The XX
•

genotype of females provides them with protection from
phenotypic manifestations of X-linked recessive disorders,
however in affected families they have a 50% chance of
·inheriting an X·linked disease gene and therefore have a
50% chance of being carriers of such X-linked disease genes.

...

,.

3

Figure 1.2

Four domains of dystrophin are represented on this tentative
~chematic

diagram. The conformation of the actin-binding,

cysteine-rich and C-terminal domains is purely speculative
and are represented as broad loops simply to illustrate that
they may adopt a more globulal structure, than the rod section.
The rod section is formed by 25 triple helical segments
(Koenig et al, 1988).

•
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Carpenter et al (1990) and Watkins et al (1988), both localised
dystrophin at or close to the plasma membrane of human skeletal
muscle. The use of both light and electron microscopy has shown
dystrophin to be located in the sarcolemma of the muscle and
immunostaining showed particular prominence of dystrophin at the
myotendinous junction (Campbell et al, 1989; .Knudson et al, 1990).
Some of the proposed functions of dystrophln are:1) A role in excitation and contraction coupling. The early localisation
studies showed dystrophin to be enriched on the T-tubules at the
triadic junction of skeletal muscle (Knudson et al, 1990; Harris et al,

'

1992).
2) Involvement in the regulation of ca++ movement. In this case it is
said the dystrophin is bound to stretch-inactivRted channels. In a

'

dystrophin deficient state, these channels remain open allowing a
continual influx of ca++. It must be noted that it is not known by what
mechanism dystrophin affects the ca++ channels (Turner et al, 1988;
Harris et al, 1992).
3) . Maintenance of flexibility and stability ot'the plasma membrane. It is
thought the C-terminus is bound tightly to the plasma membrane
?

-

glycoproteins, while the amino terminus is attached to the
cytoskeleton. This provides the plasma membrane with protection from
stretching. (Watkins et al, 1988; Harris et al, 1992) ..:

1-5

Reading frame theory

Irrespective of the role of dystrophin it has been established that the
size of the deletion does not provide information as to the severity of
the disease (Hodgson et al, 1989). It was proposed by Koenig et al

8

(1989), 1hat mutations which maintained the reading frame of mRNA
resulted in the milder BMD, while DMD occurs when the reading frame
is disrupted, due to the insertion of a stop codon. This stop codon in
DMD patients resulted in a severely truncated protein (Hodgson et al,
1989; Koenig et al, 1989). It was subsequently shown by Koenig et al
(1989), that this was not always the case. In 60 out of 70 BMD patients,
deletions in the Dystrophin gene had maintained the reading frame
and in 178 out of 188 DMD patients, deletions had disrupted the
reading frame. It was evident from these results that approximately
92% of DMD and BMD patients fitted the reading frame model.
Western blot analysis also showed that DMD muscle, when tested with
' specific carboxy terminus antiserum, gave negative results. BMD when
tested with the same carboxy antiserum gave a positive result, but with
reduced protein size and expression (Tanaka et al, 1990; Harris et al,
. 1992). This was an indication of a mutation that has maintained the
reading frame. Hodgson et al (1989), showed that the same deletion in
different patients could result in different phenotypic manifestations.
This suggested that other factors might influence the phenotypic
response to a mutation. Chelly et al (1990), suggested that alternate
splicing might explain the exceptions to the'reading frame theory.
. -·
.

1.6 ,.

Splicing
'

in higher eukaryotes some pre-mRNAs undergo alternate splicing,
which increases the number of protein products

~f

a single gene and

provides additional mechanisms for regulating gene expression
(Green, 1986). Alternate splicing can result in the skipping of specific
exons, therefore generating multiplE! mRNAs from a single pre-mRNA
(Green, 1986).

9

The process of transcription involves the synthesis of a single-stranded
mRNA molecule from the double-stranded DNA template in the cell
nucleus. Transcription of DNA is selective, with specific regulatory
sequences indicating the beginning and the end of the segments of
DNA to be transcribed. Transcription of a gene results in many
identical single-stranded transcripts containing_ both introns and exons.
This pre-mRNA then needs to have the intronic (non-protein coding
region) mRNA spliced aut before it can became mature mRNA and
subsequently leave the nucleus (Green, 1986; Padgett et al, 1986).

The process at splicing intronic RNA out of pre-mRNA to make mature
mRNA is not well understood (Ruby & Abelson, 1991 ). Small nuclear
RNA's (snRNA) are involved in this splicing. In particular a subset of
these snRNA's known as U1, U2, U4, US, U6, U7, UB, US, U1 0,
. have

been shown to form complexes with

small

nuclear

ribonucleoproteins (snRNP's). The snRNA U1 is the first to bind to the
pre-mRNA and is complementary to the consensus sequence at the S'
splice site. Consensus sequences play an important functional role in
gene expression and although the sequence may not be identical from
gene.
to gene, they do tend to share· certain features. US is
.
"~·

.

complementary to the 3' splice site. These two snRNA's along with the

-

other snRNA's and the associated snRNP's form a complex known as
a spliceosome, which causes a looping of the intronic mRNA and
subsequent splicing out of the intron, to form the mature mRNA (Ruby,
1991 ). It does this by acting as a temporary clamp to hold the two
consecutive exons together so that enzymatic splicing occurs at the
correct point. The process of spliceosome formation requires ATP
(Green, 1986; Padgett et al, 1986; Gunzel et al, 1992):

10

The 5' and 3' ends of introns contain only two universally conserved
dinucleotides, the first and last two nucleotides of the intron. The first
two nucleotides, known as the donor splice site are located at the 5'
end of the intron and consists of a Guanine and a Uracil. The last two
nucleotides, known as the acceptor splice site are located at the 3' end
of the intron and consist of an Adenine and a Guanine (see Figure 1.3)
(Green, 1986; Padgett et al, 1986).
At the exon-intron boundaries, there is also a conserved sequence
{)t

which provides binding sites for snRNA's. At the Donor site 5' end
there is an eight nucleotide semi conserved consensus sequence, two
1

residues 5' and six residues 3' from the splice point. The actual
nucleotide frequencies upon which the consensus is based are A
64%, G 73%, I G 100%, U 100%, A 62%, A 68%, G 84%, U 63%.
Beyond this region the sequence is again random (Green, 1986). At
the Acceptor site 3' end of this intron, the consensus sequence is of
variable length (greater than ten nucleotides), 1 residue 3' and a
variable number of residues 5' from the splice point, which includes a
pyrimidine rich region and the universally conserved "AG" dinucleotide
(see Figure 1.3) (Green, 1986; Padgett et

~1.

1986).

Thi>'function of introns is not well understood, although they may
"

provide extra genetic flexibility. This versatility is confelied by alternate
patterns of mRNA splicing which can generate different proteins from
the same mRNA transcript although there is no l;lpparent mutation at
the donor or acceptor splice sites. Alternative splicing_ of mRNA can be
related to tissue-specific splicing ie. different mature mRNA products
are spliced in different tissue samples {lnazu et al, 1992). Alternate

11

Figure 1.3
,Splicing of pre·mRNA results in mRNA, which then leaves the
'

nucleus. Donor and Acceptor splice sites indicate the region of
HNA to be spliced out and are universally conserved. The
donor consensus sequence is semi-conserved and necessary
'

·for accurate splicing to occur.

·. ....
•
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splicing can also occur at different times during development, resulting
again in changes in the mature mRNA transcript (Green, 1986). It is
also possible to have non-regulated splicing. For example this occurs
in the adenovirus allowing the virus to produce multiple protein
products from a single transcription unit (Green, 1986).
1. 7

Mutations in the dystrophin gene
and disease detection

Mutations at the donor and acceptor splice sites of a gene have been
shown to produce various effects in the formation of mature mRNA.
These include exon skipping, insertion of intronic sequence in mRNA

'

and partial insertions and deletions of both exons and introns into
mRNAwhich may or may-not affect the reading frame (Rees et al,1985;
Cladaras et al, 1987; Mounir et al, 1990; Takahashi et al, 1990;
Carstens et al, 1991 ).
In 30% of DMD families and 14% of BMD families there is no easily
detectable mutation (Laing, 1993). These DMD and BMD patients
therefore have point or minor mutations of the dystrophin gene, which
conventional southern analysis or

multiple~

polymerase chain reaction

(PC~) are unable to detect. These ,families must rely on linkage

analysis for prenatal diagnosis. The accuracy of diagnpsis based on

•

Jinkage analysis varies, depending on the distance of the polymorphic

.-

marker from the disease-causing mutation. Linkage analysis is also
limited by the number of affected people in a family. For example, if
only one affected person is seen in the family it is not possible to
establish linkage between markers and the disease gene and so
linkage analysis becomes useless in these circumstances. The large
size of the dystrophin gene 2.5 Mbp and other undefined factors result

14

in 11% to 12% recombination across the dystrophin gene (Abbs et al,

1990). Prenatal diagnosis of DMD/BMD families by linkage analysis
could result in errors unless tightly-linked highly polymorphic flanking
markers are used (Laing, 1993). PCR techniques have been used to
analyse microsatellites (polymorphic markers) at either end of the
dystrophin gene, to determine linkage. This method of linkage analysis
is both extremely informative and fast (Webber et al, 1990). The
problem with linkage analysis is most family pedigrees are not large
enough to show linkage of the disease with a polymorphic marker. If
the mutation is de-novo, which is estimated to be the case in 33% of
DMD/BMD patients, then linkage analysis is of no value (Laing, 1993).
The best method of offering these families accurate prenatal diagnostic
testing, would be to Identify the actual point or minor mutation in these
families that results in DMD/BMD. It is then possible to devise an
· accurate prenatal diagnostic test based on the disease causing
mutation.

Project outline

1.8

In 70% of DMD and BMD patients the conventional restriction fragment
length analysis of the dystrophin gene .by southern blots, show notable

-"

defeiions, duplications or translocatlons. This provides accurate
prenatal diagnostic tests for these families. In the othef 30% of DMD
and BMD patients there is no known deletion or 1ranslocation,
therefore for these families linkage analysis is· the only means of
providing a prenatal diagnostic test and this may not always be
informative. This 30% of patients with DMD and BMD must therefore
have a small mutation, even a point mutation which is not able to be
detected by southern analysis (Richards et al, 1991; Laing et al, 1992).

15

The project involves looking for small or point mutations, in one
Western Australian family which does not have a notable deletion
and/or translocation. If a point or small mutation is identified this will
provide the basis for an accurate prenatal. diagnostic test for this family.
It will also enable carrier females to be ide"ntified. To do this I will
perform a dystrophin gene nested amplification ·of complementary
DNA (eDNA) from seven affected individuals belonging to seven
different families. This may gi'Je an indication· of which family is best to
investigate further, with a view to developing a diagnostic test for their
, form of muscular dystrophy. In doing the project I will become familiar
with a large number of molecular techniques, polymerase chain
reaction (PCR), single strand conformation polymorphism (SSCP),
amplification refractory mutation system (ARMS) and genomic
sequencing.
1. 9

Techniques used to identify mutations

Roberts

et

al (1991) and (1992) have described a method for finding

point mutations in the dystrophin gene. Their method of detecting point
mu)ations will be used in this project ,with some slight modifications.
Messenger RNA will be extracted from muscle

inste~d

of peripheral

blood lymphocytes. Reverse transcription of mRNA to produce
eDNA
,.
and nested PCR of the dystrophin gene will be carried out using the
nested primers specified by Roberts et al (1991 ).
If no mutation is evident after nested PCR, then SSCP analysis will be
attempted. Richards and Friend (1991 ), showed SSCP analysis of

.
DNA could be used to determine carrier status of dystrophic women.
Orita et al (1989a), noted that SSCP analysis could be used to detect

16

single base changes in sequences under 200 base pairs (bp). SSCP
is used to analyse the eDNA after it has been amplified [PCR], because
single strand DNA migrates according to the nucleotide sequence
which in turn determines the conformation of the DNA and
subsequently the speed of migration. Therefore a single base change
in single-stranded DNA may cause a conformation change, which will
lead to a change in migration speed during electrophoresis. A single

..

base change in double-stranded DNA would not cause a change in
migration with normal electrophoresis (Orita et al, 1989b; Baldwin et al,
1992).
, Once nested PCR or SSCP has determined an area of the dystrophin
gene to be polymorphic, it is necessary to sequence the genomic DNA
for that

area and determine whether or not there is a sequence

change from the published eDNA sequence and whether that
particular change could result in the clinical manifestation of DMD or
BMD in the individual (Rao & Sanders, 1992).
The final phase of the project will involve providing the families with
an accurate prenatal diagnostic test. This could be either using SSCP
to .characterise
the effect of the mutation o~ all the family members, or
..
~

ano'tlier diagnostic test, known as amplification refractory mutation

,.

•

system (ARMS). The ARMS method uses primers specific for the
mutation, to amplify the mutant allele or the normal allele (Wenham et
al, 1991).

17

CHAPTER 2: RNA EXTRACTION AND eDNA SYNTHESIS

2.1

Introduction

During ribonucleic acid (RNA) extraction from tissue there are many
opportunities for contamination with RNAases. RNAases are enzymes
which can degrade the RNA in the tissue and during the extraction
procedure (Sambrook et al, 1989). The history of the frozen tissue
used in this project and its handling at the time before freezing was not
known and may have resulted in contamination with RNAases. It was
therefore important to minimise the introduction of RNAases in the
, extraction procedure, to limit degradation of the RNA still present in the
tissue. This was done using sterile technique and RNA dedicated
equipment and solutions. All further analysis carried out on this RNA,
was done using the polymerase chain reaction (PCR) technique. PCR
requires only small amounts of mRNA to be converted into eDNA for
subsequent amplification to occur successfully. As the products being
amplified were approximately 1250 bp long, it was necessary that
RNAase activity/presence was minimised so as to allow the production
of this relatively large eDNA transcript.
The 'RNA extracted from the muscle' biopsies does not have any
r

~

intronic sequence and is used as a template in thEi'.production of
eDNA. Converting the mANA to eDNA, by using the enzyme reverse
transcriptase, reduces the sequence information,: making it easier to
find minor mutations. Genomic DNA coding for the dystrophin protein
consists of 2500 kb whereas the eDNA which codes for dystrophin is
only 11 kb long or 14 kb if promoters and 3' untranslated regions are
included (Koenig et al, 1987) .

.18

The conversion of RNA to DNA occurs within a group of viruses, known
as retroviruses. These viruses have a genome composed of single·
stranded RNA. Upon entering a cell the retrovirus Is uncoated and the
RNA is copied into DNA by a unique viral enzyme called reverse
transcriptase (Gelehrter and Collins, t990, p.238). This retroviral
enzyme can also be used to convert mANA extracted from cells to
eDNA, resulting in a DNA transcript with no intronic sequence. This
process of converting single·stranded RNA to double-stranded DNA is
known as reverse transcription (Watson et al, 1987, p.90).
Reverse transcription of mANA extracted using RNAzol (Biotecx lab) or
, the GuHCI (guanidine hydrochloride) methods, was carried out using
avian myeloblastosis virus reverse transcriptase (AMV-RTase),
supplied by Promega Corporation. This enzyme synthesises DNA in
the 5' to 3' direction from a single stranded RNA template, using a
short primer to initiate synthesis. AMV-RTase works efficiently at 42°C,
which allows RNA's rich in secondary structures to be copied more
efficiently than the murine enzyme which works at 37°C (Sambrook,
1989). The problem associated with both these reverse transcriptase
enzymes is the lack of 3' - 5' exonuclease. activity, which provides an
editi~g function and therefore the presence of high concentrations of

dNTP:s and Mg++ may lead to mis-incorporation (Sambrook et al,

•

1989). AMV-RTase enzyme and associated 5x buffer were supplied by
'

Pro mega Corporation. The 5x buffer supplied has the concentration of
dNTP's and Mg++ optimised and therefore reduces any chance of mlsincorporation during eDNA synthesis.

19

2.2

Materials and Methods

Two methods of RNA extraction were used. RNAzol (Biotecx lab) and a
modified GuHCI method (Chirgwin et al, 1979).
Note: all reagents used in this honours project were of analytical
grade.
2.2.1

RNAzol (Biotecx lab)

This is a new method of RNA extraction and the ingredients which
make up RNAzol remain a closely guarded secret of Biotecx Inc. The
benefit of this method of RNA extraction is that it requires minimal steps
and time in order to get good RNA yields. The RNA extraction consists
of four steps :·
1.

Homogenisation (tissue)

2.

RNA extraction

3.

RNA precipitation

4.

RNA wash

The RNAzol method of extracting RNA can be completed within 2
hours. The methodology used for the ext('iCtion of RNA in this case
was

hi

compliance with the RNAzol preduct information pamphlet and

...

is as follows:-

A muscle sample (5·1 Omg) was placed in a 1.5ml reaCtion tube and
200ul of RNAzol was added. The muscle was then homogenised using
a sterile, disposable, plastic homogeniser. 20ul of chloroform was theD
added to the homogenate and the sample shaken vigorously for fifteen
seconds. The sample was then left on ice for five minutes and then
spun down at 11500g (4°C) for 15 minutes. At this stage two phases
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formed, an upper colourless phase and a iower blue phenolchloroform phase. RNA remains in the upper colourless phase. The
upper phase was then transferred to a fresh 1.5ml reaction tube, with
an equal volume of isopropanol and then stored for 15 minutes at 4°C.
The sample was then spun in a centrifuge at 11500g (4°C) tor 15
minutes. The RNA formed a white-yellow pellet at the bottom of the
tube. The supernatant was then removed with a

micro-~ipette

and the

pellet washed in 500ul of 75% ethanol, by vortexing and subsequent
centrifugation at 71 OOrpm (4°C) for 8 minutes. The 75% ethanol was
removed and the RNA pellet was dried under vacuum for 10 minutes.
Finally, the dried RNA was resuspended in 50ul of double distilled
water (DOW).
2.2.2

Modified GuHCI RNA Extraction

. This method of RNA extraction is described in Chirgwin et al (1979)
and requires more preparation and time than the RNAzol method. The
first step involves making up the three solutions required in the
extraction procedure.
2.2.2.1 Solutions For RNA Extractiol)·
6M . '

Solution 'A'

200mM

Solution 'B'

NaAc pH 5.'2'- 6.0

10mM

B-ME

6M

GuHCI

200mM
10mM
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GuHCI

NaAc. pH 5.2 - 6.0
EDTA

7M

Solution 'C'

Urea

100mM

Tris

200mM

NaAc pH 5.2- 6.0

0.5%
10mM

pH 8.0

. SDS
EDTA

2.2.2.2 GuHCI RNA Extraction Procedure
The volumes of each solution required for the extraction of RNA are

'

based on a starting muscle sample of 5 to 1Omg. Throughout the RNA
extraction the samples and solutions were kept on ice, whenever
possible .
. The muscle sample was homogenised in a 1.5ml reaction tube, with
500ul of solution 'A', then 500ul of 100% ethanol was added. This
solution was then mixed well and chilled at -80°C for 15 minutes. The
sample was then spun at 13650g (4°C) for 15 minutes, the
supernatant discarded and the pellet resuspended in 300ul of solution
'6'. The pellet was then homogenised again in solution '6', after which
.

300ul of 100% ethanol was added. Tlils solution was then mixed well
and chilled at -B0°C for 15 minutes. Next, the sample wci's then spun at
13650g (4°C) for 15 minutes, the supernatant was discarded and the
pellet resuspended in 400ul of solution 'C' alter which 400ul of
buffered phenol and 400ul chloroform:isoamyl alcohol_ 24:1 was added
to the pellet in solution 'C'. This solution was mixed well and left on ice
for 10 minutes. Spinning the solution at 13650g. (4°C) for 15 minutes
resulted in two phases,

w~h

the top aqueous phase containing the

RNA. This top aqueous phase was transferred to a fresh 1.5ml reaction
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tube containing 800ul of 100% ethanol. The ethanol and RNA
aqueous phase were mixed well and chilled at -20°C overnight. The
following day, the aqueous phase with ethanol was spun at 136SOg
(4°C) for 1S minutes and the supernatant discarded. The RNA pellet
was washed in 300ul of 70% ethanol, the 70% ethanol removed and
the pellet dried under vacuum. The RNA pelle.t was then resuspended
in SOul of DDW.

2.2.3

eDNA Synthesis from mRNA

Reverse transcription is the process of converting single stranded
mRNA into double stranded eDNA using the retroviral enzyme reverse
transcriptase. This eDNA doesn't include any intronic sequence as this
was spliced out of the mature mRNA (Sambrook et al, 1989).
Using the RNA extracted by the RNAzol or modified GuHCI methods,
4ul of RNA was added to 4 units of AMV-RTase, 2SOng of random
hexamers, Sui of Sx buffer as supplied by Promega and then the
reaction was brought to volume with DOW. The reaction was then
incubated for 5 minutes at room temperature followed by 60 minutes at
42°C. The eDNA was then diluted 1:20 in DDW and stored at 4°C.

2 .2)1

,.

Gel Electrophoresis

•

DNA and RNA migrates according to descending size,
.. from the
cathode (-ve) towards the anode (+ve) in response to an electric
current in either an acrylamide or agarose gel. In order to increase
separation of the different sized DNA and RNA it is necessary to vary
the gel concentration, running time and voltage (Sambrook et al,
1989).

23

2.2.4.1 Making Agarose gel
Increasing the agarose concentration makes for a denser gel. The
greater the agarose concentration, the slower the DNA travels through
the gel matrix. Also the size of the DNA sample being fractionated
determines the agarose concentration needed, the smaller the DNA
sample the greater the concentration of agarose required (Sambrook
et al, 1989).
1% Agarose gel
i

1g ofagarose in 100ml of 1x TAE butter

· 2% Agarose gel
2g of agarose in 1OOml of 1x TAE buffer
3% Agarose gel
3g of agarose in 100ml of 1x TAE buffer
Agarose and 1x TAE buffer were added to ~·stock bottle, with the lid on

locis~ly. The solution was boiled in a,microwave oven and agitated
until all the agarose had dissolved, then stored in a d'Y"oven at 65°C
until ready to pour.

2.2.5

Running RNA on Agarose gel

A 1% agarose solution was poured onto a gel tray to a depth of 5 to
10mm. A gel comb was then placed in the solution, 1cm in from one
end and to a depth of approximately 1 mm from the l)ase of the tray.
The agarose solution was then left 15 minutes at room temperature to
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set. Once set, the comb was removed and the gel placed in a gel tank
with 1x TAE buffer covering the gel. 1Oul of the RNA sample, along
with 2ul of ficoll loading buffer (6x), was loaded into each well. The gel
was then run for 45 minutes

at 100 volts(v) and stained with ethidium

bromide, which binds to DNA/RNA. After staining, the gel was
observed under an ultra-violet (UV) light (305nm Transilluminator),
which fluoresces the DNA and RNA.
2.3

Results

The RNA extraction was carried out using two methods, (i) RNAzol
system and (ii) modified GuHCI method. The RNAzol method, although

'

very quick (total extraction of RNA in less than three hours) did not
yield RNA of sufficient size and quantity as subsequent nested PCR
analysis showed. In Figure 2.1 the "RNAzol1" and "RNAzol 2" lanes
. show faint bands, indicative of 18s ribosomal RNA. The second
method of RNA extraction was a modified GuHCI method (Chirgwin et
al, 1979). This method also extracted DNA. The "GuHCI1" and "GuHCI
2" lanes in Figure 2.1 shows the DNA extracted with no sign of RNA.
However, PCR analysis showed this RNA extraction procedure worked
well. A third method of RNA extraction, a·hybrid of RNAzol and the
modified GuHCI methods was tried iri 'the hope of providing a taster
and more efficient method of extracting RNA. This 11fethod did not
prove successful, as the yield of RNA was not sufficient to allow further
nested PCR analysis (data not shown).
eDNA synthesis was achieved using AMV-RTase. The conditions
remained constant for all RNA transcripts whether extracted by RNAzol
or the modified GuHCI method. It was only after the arr1plificatlon stage
of the eDNA by PCR that it was possible to determine whether the RNA
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Figure 2.1
A 1% agarose gel loaded with 1Out aliquots of the RNA
extracted from normal muscle by the RNAzol and GuHCI
i

·methods. The numbers 1 and 2 for RNAzol and GuHCI
represent two different muscle samples, which are normal for
dystrophin. The bands in sample GuHCI 1 and GuHCI 2
. represent DNA extracted in this procedure. Lamda marker
digested with Pst I.

...
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Lambda Marker
RNAzol 1
RNAzol 2
GuHCl 1
GuHCl 2
Lambda Marker

extraction and the eDNA synthesis actually worked. The best method
of extracting RNA from small amounts of frozen tissue proved to be the
GuHCI method although it was more time consuming than the RNAzol
method.
Extraction of RNA from 5 to 1Omg of muscle tissue resulted in very few
RNA transcripts. It was not possible to determine the presence of tRNA
and rRNA by running an aliquot of the RNA on a 1% agarose gel (see
Figure 2.1 ). All RNA samples were converted to eDNA (reverse
transcription), in order to perform further analysis. This was done
because PCR amplification requires only a few full length transcripts to
, produce multiple copies of eDNA required for further analysis.

2.4

Discussion

Factors that influence the quality of RNA extraction include the type of
sample, storage of the sample and the extraction procedure. As
muscle samples from affected DMD/BMD patients were in such small
quantities, it was necessary to optimise the extraction procedure by
trying various RNA extraction techniques on normal muscle samples
which had been stored in the same manoer as the affected muscle
samP.Ies (-80° C). Once the RNA extra9tion and eDNA synthesis were
optimised it was then decided to proceed with the

aff.~cted

samples.

Three methods of RNA extraction were tried on normal muscle

-

samples, (i) RNAzol (ii) modified GuHCI and (iii)a hybrid of RNAzol
and GuHCI methods. The RNAzol

method and the hybrid

RNAzoi/GuHCI methods when used on small amounts of frozen tissue
(5-1 0 mg), did not provide sufficient good quality mRNA to do further
PCR analysis using the nested primers specified by Atlbs et al (1991).
The modified GuHCI method was able to produce RNA of sufficient
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quality to allow further PCR analysis. When this RNA was extracted
and an aliquot was run on a 1% agarose gel to determine (i) whether
there was RNA present and (ii) if it was present whether it was
degraded. The small amounts of tissue being used 5-10mg in these
RNA extraction procedures, did not produce sufficient RNA for the
bands to be visualised. RNA when run on an agarose gel should give
three prominent bands, representing 5s, 18s and 28s ribosorotal and
transfer RNA (Alberts et al, 1983 p.209). It was necessary to go on and
produce the eDNA and do a nested amplification in order to determine
whether the RNA extraction had worked efficiently.
, Not all DMD/BMD patients will submit to a biopsy, therefore, although
muscle may provide the most abundant quantity of dystrophin mRNA
transcript (Chelly et al, 1988), it is possible to obtain dystrophin mRNA
from lymphocytes (Roberts et al, 1990). This may prove to be a much
more practical when looking for mutations in other Western Australian
dystrophic families.

...

,.

,.
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CHAPTER 3:

3.1

NESTED AMPLIFICATION

Introduction

Polymerase chain reaction (PCR) is a new development in DNA
technology, with the ability to amplify a short sequence of DNA from a
complex mixture containing:1)

Target DNA

2)

Taq Polymerase

3)

5x mix (buffer, nucleotides and
MgCI2)

4)

'

Primer

5)

6)

Paraffin overlay (stops evaporation)

It is first necessary to synthesise two short oligonucleotide primers
based upon the known sequence of the region. These primers are
chemically synthesised and are usually between 20-35 nucleotides
long. Polymerase chain reaction takes place by heating the target
DNA, which denatures it int.o single strands. The reaction is then
cooled to a preset annealing tempe:rature which allows the
oligon"ucleotide primers, present in high concentration, to anneal to
their complementary DNA strands (Bej, 1991 ). Once annealing is
completed, extension of the DNA occurs with nucleotid"s being added
to the primer by the enzyme Taq polymerase. The Taq enzyme is able
to withstand temperatures as high as 95°C and is derived from a
bacteria found in hot springs (Thermus aquaticus) (Erlich, 1989).
Extension only occurs when the primers anneal to the target DNA,
which then allows the Taq polymerase to synthesise a DNA strand
using the target DNA as a template. This whole procedure is easily
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cycled, with each cycle taking about 5 minutes and the synthesised
product in one cycle can serve as a template in the next. At the
completion of each cycle the DNA sequence specified by the primers,
will have doubled. As many as 30 to 40 cycles can be carried out
without the need to add fresh enzyme or primers. 30 cycles results in
approximately 1 billion copies of the target DNA and all this occurs in a
single PCR tube (Gelehrter & Collins, 1990, p. 82).
Nested amplification is a modified PCR. It involves two sets of primers,
used in two separate PCR reactions. The first reaction is a standard
PCR, usually carried out for 30·35 cycles. The nested amplification,
i

uses primers which are internal to the first round primers. It also uses a
diluted first round amplification product as target DNA in the nested
amplification. The product that results is the same size as one obtains,
when only the nested primers and the original target DNA are used in
/

· ' a PCR reaction (see Figure 3.1) (Roberts et al, 1991 ).
The nested amplification method provides both a double check on the
sequence being amplified and results in a much more specific
amplification. The conditions of amplification are not extremely
stringent, but because the second round amplification is of a product
slightly smaller and contained within ihe first round amplification, this
increases the specificity of the bands produced.

•

..
The nested PCR method of amplification is able to amplify up
extremely small amounts of the template DNA billions of times, if the
eDNA produced by reverse transcription was of suffiCient quality. It is
then possible to run the amplified DNA on an agarose gel and after
ethidium bromide staining, visualise it under a UV li~ht (Bej, 1991).
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Figure 3.1
Nested Amplification: The eDNA is amplified primarily with a
primer mix consisting of primer A and D, this amplified product

'1s then diluted and used as target for the nested amplification.
A primer mix consisting of primer B and C is then used in the
nested amplification, this nested product can then be
electrophoresed on an agarose gel, stained with ethidium
bromide and viewed under a UV light source .

..

...

32

Primer C
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3'

3'

5'
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The accuracy of PCR analysis depends upon a number of factors
including the quantity of template, the concentration of the dNTP's,
primer concentration, Taq Polymerase concentration and MgCI 2
concentration (Innis et al, 1990). The conditions used in the nested
PCR and all the other PCR reactions were choscln in order to minimise
the chance of mis·incorporation during amplification.

Materials and Methods

3.2

All PCR reactions used the following 5x Amplification mix unless
olherwise stated.
The 5x Amplification mix consists of:1mM dNTP
5x Reaction Buffer (Biotech)
10mM MgCI 2

Reaction Concentration:200uM dNTP
1x Reaction Buffer (Biotech)
2mM MgCI2

3.2.1

..

Amplification of dilute ci>"NA

•··

Amplification of the eDNA (dilute) involved a primary amplification with

.

external primers. This reaction was subsequently diluted 1 :200, so as
to reduce carry over effect of external primers, with DDW and a Sui
aliquot used in the secondary amplification in which p·rimers internal to
the primary amplification primers were used. The approximate length
of the final amplified product was 1250 bp. This procequre is known as
nested amplification. Table 3.1 indicates the primers used in order to
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Table 3.1

Primers used in nested amplification
Sequence (5' to 3')

i

Primary/Nested

Position

Exon

ATGCTTTGGTGGGAAGAAGTAG
GAGAGGTAGTTACTTGACGGT

p
p

208·230
1197·1218

2·10
2·10

TTATGAAAGAGAAGATGTTCAA
CTTGTCTTCAGGAGCTTCCAA

N
N

237·259
1171-1192

2·10
2·10

CGATTCAAGAGCTATGCCTAC
GCGAGTAATCCAGCTGTGAAG

p
p

1091·1111
2399·2419

9·18
9·18

CCTCTGACCCTACACGGAGC
CAGTTATATCAACATCCAACC

N
N

1134·1153
2376·2396

9·18
9·18

CATGCTCAAGAGGAACTTCC
CTGAGTGTTAAGTTCTTTGAG

p
p

2300·2319
3599·3619

17·25
17·25

GCAGATTACTGTGGATTCTG
GTCTCAAGTCTCGAAGCAAAC

N
N

2344·2363
3574·3594

17·25
17·25

CTAGAAATGCCATCTTCCTTG
CTCAGGAGGCAGCTCTCTGG

p
p

7583·7603
8871-8890

51·58
51-58

CTG¢TCTGGCAGATTTCAAC
CTCCTGGTAGAGTTTCTCTAG

N.
N

7617-7636
8849-8869

51-58
51-58

...

-------~~--------------------------------------------------------------------------------------

•

·(Roberts et al, 1991)

e
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do the nested amplification of exons t-10, 9-18, 17-2S, St-SB. All
primers were synthesised at this laboratory on a Cyclone Plus DNA
Synthesizer (Milligan I Biosearch).

3.2.2

Primary amplification of the dystrophin transcript

To a O.Sml PCR tube was added Sui of Sx buffer, t3.Sul DDW, 1ul of
the outer primers (70ng), O.S units of Taq polymerase (Biotech) and Sui
of dilute eDNA. The reaction mix

wa~

.hdn vortexed for one second

and a drop of paraffin added to overlay the reaction. The primary
amplification was for 3S cycles of 94°C for 30 seconds, 5S°C for 1
, minute and 72°C for 2 minutes (the initial denaturation step at 94°C
was carried out for S minutes). At the end of the primary amplification
the PCR product was diluted 200 fold by adding DDW to the PCR tube
and then vortexing. This provided the target for the secondary
amplification.

3.2.3

Nested amplification of the dystrophin transcript

The second round polymerase chain reaction was essentially the
same as the primary amplification except_ ·sui of the diluted primary
amplification mix was used as the target instead of the Sui of dilute

.

.

'

cDNA,.that was used in the primary amplification. Also _jhe number of

•

cycles used in the secondary amplification was reduced to 30 cycles.

3.2.4

Molecular weight markers

In order to determine the size of the DNA fragments during gel
electrophoresis it was necessary to run standards which indicate the
approximate size of the DNA samples run on the gel.. Lambda phage
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•

when cut with the restriction enzyme Pst I provided a high molecular
weight marker and pUC 19 cut with Msp I provided a low molecular
weight marker (see Figure 3.2).

3.2.4.1 Lambda cut with Pst I
To a 1.S ml reaction tube was added; 1SOul of 1Ox buffer "3", 30ul of
0.1 M spermidine, 1Sul of 1Omg/ml BSA, 9ul of 20 units/ul Psi I
enzyme, 996ul of DOW and 300ul uncut lambda 500ng/ul. The tube
was then vortexed lightly and incubated for 8 hours at 37°C to allow
digestion to take place. The lambda cut with Psi was then ethanol
precipitated and resuspended in 6ml of Fico II 1x loading buffer. Sui of

'

marker was loaded on all agarose gels.

3.2.4.2 pUC 19 cut with Msp I
, To a 1.S ml reaction tube was added; 1SOul of 10x buffer "A", 30ul of
0.1 spermidine, 1Sul of 1Omg/ml BSA, 9ul of 20 units/ul Msp I enzyme,
996ul of DOW and 300ul of uncut pUC 500ng/ul. The tube was then
vortexed lightly and incubated for 8 hours at 37°C to allow digestion to
take place. The pUC cut with Msp I was then ethanol precipitated and
resuspended in 1.5ml of Fico II 1x loading buffer. The DNA

.

··:.

concentration was much less than sbong/ul, due to the presence of

RNA

in the uncut pUC sample. The RNA in the pUC safijple resulted in

amuch greater DNA reading when measuring absorbance at 260nm
in a spectrophotometer. Sui of the marker was loaded on all agarose
gels.
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Figure· ' 3.2
Molecular weight markers: Lambda cut with the enzyme Pst I
(High molecular weight marker) and pUC 19 cut with Msp I
·(Low molecular weight marker).

,.

,··
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Lambda cut with Pst I
4789 . 4749
2556 . 2443
1886

-

--

1159
805
468
339

---

11500
2838
2190

1700

Number of
Base Pairs

1093
514
448

pUC cut with Msp I
501 . 489

-

404
331

-

242

-

190

-

147
111

Number of
Base Pairs

3.2.5

Electrophoresis of nested products

The nested amplification products were run on a 2% agarose gel, for
one and a half hours at 100 volts in 1x TAE buffer. 2ul of the sample ·
was mixed with 2ul of fico II loading buffer (1 x) and loaded to each
lane. The gel was visualised by staining with ethidium bromide, which
will fluoresce the DNNRNA under UV light (305nm Transilluminator).
3.3

Results

Figure 3.3 shows the nested amplification of eDNA, exons 1 to 10,
derived by reverse transcription of RNA extracted using GuHCI method
, on normal muscle samples. Figure 3.3 is also evidence that the RNA
extraction and eDNA synthesis worked with normal muscle samples
(no known deletions). Although the primary amplification lanes in
Figure 3.3 samples show no evidence of any amplified product, there
is an ion front which is a characteristic of the loading buffer that was
used. Subsequent dilution of this primary amplification product
followed by nested amplification resulted in a strong signal for the
nested products corresponding to exons 2 to 10 of the dystrophin
gene.
Figure 3.4 shows the nested amplified products of seven individuals
from different families (A- G) who have point or minor mutations in the
dystrophin gene. Amplification of exons 9-18 show patient D as having
no product, this is consistent with the amplification:of exons 17-25 and
51-58 which also indicate no products for patients D (see Figure 3.4).
This indicates either the RNA extraction or the eDNA synthesis hasn't
worked, or that this patient lacks all these exons. As patient D has
already been tested using conventional southern blot· analysis, which
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Figure 3.3
Nested amplification of exons 2 to 10 from eDNA normal for
dystrophin. 1 and 2 signify two different eDNA samples, which
are normal for the dystrophin gene. Amplification was done
using nested primers to amplify exons 2 to 10 of the dystrophin
·gene. The samples were run on a 2% agarose gel at 100 volts
for 1 hour. Lambda marker digested with Pst I.

,.

•
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Lambda Marker
Primary Amplification
Primary Amplification
Nested Amplification
Nested Amplification
-ve Control
Lambda Marker

1
2
1
2

•

Figure 3.4
Nested amplification of eDNA derived from patients from
different families who have either DMD or BMD. A to G signify
different patients, the exons amplified for each of these
patients are 9-18, 17-25 and 51-58 respectively. The samples
were run on a 2% agarose gel at 100 volts for 1 hour and 15
minutes. Lambda marker digested with Pst I.
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did not indicate any major deletions, it was therefore assumed that the
RNA extraction or eDNA synthesis had not worked. No product is
evident for patient E exons 51-58 (see Figure 3.4). As the eDNA of
patient E amplified exons 9-18 and 17-25 this would indicate either;
that the eDNA transcript for exons 51-58 was not in sufficient quantity
to provide a target in the primary amplification, there was human error
in the setting up of the ampliiication, there was a mutation in the primer
binding sites, or a major deletion of exons 51 to 58. A major deletion of
this size would have been picked up using conventional southern blot
analysis. Excessive amplification of exons 51-58 for patients (A to G)
has resulted in a strong signal for all patients, with some non-specific

'

bands. Figure 3.4 shows patient G as having two distinct bands for
exons 17-25, one band corresponding to the normal sized product and
also a smaller product which is of the same intensity yet approximately
90 bases smaller.

Discussion

3.4

It was shown in Figure 3.3 that by using nested amplification it is
possible to amplify small amounts of target. Although at the end of
primary amplification no signal is evident, this primary amplified

-

product was then diluted prior to being used as target DNA for the

..

"

nested amplification. As noted earlier in 3.2.1 dilution lakes place so
that the primary amplification primers do not interfere :in the nested
amplification otherwise this could result in a second larger product
specified by the external primers also being amplified.
When nested amplification of seven individuals (figure 3.4; A to G)
who had either DMD or BMD was done using primers that amplified
exons 9-18, 17-25 and 51-58 of the dystrophin gene, it was evident
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'
that patient G had two amplified products for exons 17-25, one a
normal size product and a second product approximately 90 bp
smaller. The doublet band in Figure 3.4 patient G, exons 17-25
indicates that the two transcripts are found in equal volume in the
muscle. Dr Steve Wilton showed by repeating this nested reaction with
a decrease in the number of PCR cycles that the quantity of the
alternately spliced transcript was approximately nine fold higher than
the normal transcript (data not shown). In order to reduce the nonspecific banding in Figure 3.4 and give a clearer quantitative indication
of both transcripts, it would be necessary to reduce the number of
cycles either in the primary or secondary amplification or increase the
' dilution of the primary amplification, prior to using it as target in the
nested amplification.
Exon 19 is 88 bp long and it was considered a good location for
looking for a mutation, as all the other exons from 17 to 25 were over
100 bp (Koenig et al, 1988).
It is also important to note that not all muscle samples from the affected
DMD/BMD patients were able to be amplified using nested PCR. This
indic~tes

the difficulty of trying to extract RNA and then produce viable

eDNA in order to amplify transcripts of the dystrophin gene, which are
over 1'2oobp.

•
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Chapter 4:

4.1

SEQUENCING

Introduction

The nested amplification of exons 17-25 indicated that the mutation in
patient G was under 100 bp. Analysis of the eDNA transcript for exons
17 to 25 indicated exon 19 as an ideal location to search for this
mutation as it was 88bp, while all the other exons in the moe. were
over 100 bp (Koenig et al, 1988). It was decided to sequence exon 19
and part of intron 18 and 19, from genomic DNA in an attempt to
determine the site of the mutation. The entire sequence of the eDNA
transcript for the dystrophin gene is known (Koenig et al, 1988),
making comparison of our exon sequences with the normal transcript
easy. It was also necessary to sequence genomic DNA from a patient
who is normal for dystrophin, in order to determine differences in
intronic sequence that may also have occurred.
The Sanger sequencing method involves using four separate stop
reactions, one for each nucleotide 'A', 'C', 'G', 'T', in four separate PCR
reactions. Included in the 'A' stop reaction are the normal dinucleotide
triphosphates (dNTP's). which are required for normal amplification
reactions, with the addition of dideoxynucleotide ATP (ddATP)
(Gelehrter and Collins, 1990, p. 87). In the 'A' stop reaction the end
labelled primer anneals to the target DNA and the complementary
strand is synthesised using Taq Polymerase. When the ddATP is
incorporated into the growing chain, during PCR, synthesis of that
molecule stops. The ddATP is randomly incorporated into the growing
chain producing amplified products of different sizes, dependant on
when the ddATP is incorporated during each PCR cycle. The same
process takes place for the other three nucleotide stop reactions ('C',
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'G', 'T'), but these reactions have dideoxynucleotide CTP (ddCTP),
dideoxynucleotide GTP (ddGTP), dideoxynucleotide TTP (ddTTP)
respectively, to stop each reaction (Gelehrter and Collins, 1990, p.87).
The four stop reactions, if run in separate lanes on a polyacrylamide
gel and then exposed to X-ray film, will produce a ladder of oligomers
of different lengths from which the DNA sequence can be read.
Reading from the bottom of the gel upwards, each band represents the
complementary base found on the target DNA moving in a 5' to 3'
direction away from the primer (see Figure 4.1) (Erlich, 1989).
The Genesis sequencing system (Biotech) was chosen because of its
simplicity in setting up the four stop reactions. The inclusion of a single
dideoxynucleotide in each of the stop reactions effectively terminates
the DNA chain elongation at the base complementary to the ddNTP.
This is due to the ddNTP lacking the 3'-0H group that is necessary for
continued chain elongation (Watson et al, 1987, p. 276). The use of
PCR in the sequencing increases the speed and sensitivity of
sequencing.

4.2

Materials and Methods

A 500ml stock of 6% denaturing acrylamide solution, for sequencing,
was made by adding; 28.5g acrylamide, 1.5g bis-acrylamide, 21 Og
urea and 425ml DDW to a beaker and the contents stirred until all the
reagents were dissolved. Once dissolved, 40g of mixed bed resin was
added and stirred slowly for 30 minutes at room temperature. A funnel
and filter paper were then used to filter the acrylamide from the mixed
bed resin. DDW was then added to the mixed bed resin and filter to
bring the volume of acrylamide up to 450ml. Fin811y, SOmis of 1Ox TBE
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Figure 4.1
"The DNA sequencing method developed by Sanger. Using a
primer homologous to one end of the DNA strand to be
sequenced, the complementary strand is synthesized using
DNA polymerase. Small amounts of dideoxynucleotide
(ddATP, ddCTP, ddTTP, ddGTP) are included in four separate
such reactions; when a dideoxynucleotide is incorporated into
a growing chain, synthesis of that molecule stops. Separation
of the resultant labelled fragments in four lanes of a
polyacrylamide gel, followed by exposure to X-ray film, allows
the sequence to be read off directly" (Gelehrter and Collins,
1990,- p. 87).
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was added to the acrylamide mix which was then stored at 4°C in a
bottle wrapped in aluminium foil.

4.2.1

6% Denaturing acrylamide gel for sequencing

SOmis of 6% denaturing acrylamide solution was prepared to pour a
Poker Face acrylamide gel for sequencing analysis.
SOmis of the 6% denaturing acrylamide stock solution was added to a
1OOml beaker. 170ul of TEMED and 170ul of 25% ammonium
persulphate (APS), which had both been stored at 4°C, were added to
the beaker and mixed gently. The TEMED and the 25% APS catalyse
the polymerisation of liquid acrylamide into gel acrylamide within 5
minutes. The acrylamide solution was then drawn up in a 1OOmi
syringe and injected between the two glass plates used in the Poker
Face electrophoresis system (Hoefer), making sure not to leave air
bubbles between the plates. The comb was then inserted
approximately 5 to 1Omm into the gel mix. Once the gel had formed, a
moist piece of paper was placed over the comb and the top of the gel
wrapped in gladwrap to keep in the moisture. This gel was then stored
at room temperature for up to one week.

4.2.2

Cycle sequencing (Biotech)

The Biotech Genesis sequencing kit provided a simple and effective
means of analysing DNA sequences. The sequencing protocol was
carried out according to the Biotech Genesis informaf1on pamphlet with
some slight modifications. The volume of sterile water was reduced to
14.25ul, 2.25ul of template DNA was used which is approximately
20ng of DNA and only 1.5ul of end labelled primer was used. These
changes in the Biotech protocol were made to rectify the master mix
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concentrations, which were incorrect in the Biotech protocol pamphlet.
All solutions except for the end labelled primer and target DNA
wereprovided in the Genesis sequencing kit. Genomic DNA was
extracted from lymphocytes (Jacobsen, 1992). The end labelled primer
was donated by Dr Steve Wilton. This primer sequence was specified
by Abbs et al, (1991) and designated primer sequence:(19 F)orward

[ 5' TICTACCACATCCCATTTTCTTCCA 3']

Four 0.5ml PCR tubes were labelled A, C, G, T, and then 4ul of each
stop mix was added to the appropriate tubes. The tubes were then
placed on ice until required. Next, a master mix was made up in a 1.5
ml reaction tube, by adding in order the following components:
14.25ul DDW, 1Oul 5x sequencing buffer, 2.25ul of template DNA
(20ng), 1.5ul of end labelled primer (30ng/ul) and 2ul of Taq
polymerase (2units/ul). The master mix was gently mixed and Sui
transferred to each of the four stop mixes. Then each of the stop
reactions was overlaid with one drop of paraffin oil. The four stop
reactions were then placed in a thermal cycler and the following
program was run :94°C for 2 minutes

x1

94 °C for 30 seconds

x20

55°C for 30 seconds
70°C for 1 minute
94°C for 30 seconds
70°C for 1 minute
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x1 0

Sui of Formamide loading buffer was then added to each of the stop
reactions ("A", "C", "G", "T") through the paraffin overlay and gently
mixed by pi pelting up and down.
4.2.3

Running sequencing gel

The sequencing products from the Genesis system were fractionated
on a 6% denaturing polyacrylamide gel, using the Poker Face
electrophoresis system.
The 6% denaturing polyacrylamide gel was pre-run (to warm gel to
45°C) for 30 minutes in 1x TBE buffer at 1400 volts and the lanes
marked before the comb was taken out. The lanes were then flushed
out with the 1x TBE, using a syringe, in order to remove urea and
bubbles from the wells. Stop mixes made using the Genesis
sequencing kit (Biotech) were incubated at 94°C for 5 minutes and 2ul
of each stop mix ("A", "C", "G", "T'') was loaded into consecutive lanes.
The gel was then run at 1400 volts for 4 hours.

4.2.3.1 Fixing, drying and exposing polyacrylamide gels.
The polyacrylamide gel was then fixed in a 10% acetic acid, 10%
methanol solution, by pouring 1 litre of the fixative over the gel in 15
'

minutes. Once the gel was fixed it was removed from the glass plate
with 3mm blotting paper. The blotting paper was placed on the gel and
lifted off taking the gel off the glass plate. Gladwrap was carefully
placed over the gel. The gel was then put in a gel dryer (Hoefer) for 3
hours at 80°C at which time the gel had dried to the 3mm blotting
paper. An X-ray film (Cronex 4 - DU PONT) was then exposed to the
gel for 10 to 24 hours at -80°C, dependant on how much
the reaction, with an intensifying screen.

53

32

P was in

4.3

Results

In Figure 4.2 there is some cross-banding close to the mutation site
making some of the sequence hard to distinguish. The "A" to

··c·· base

change is clearly visible and had the gel been allowed to run further,
this would have increased separation of the relevant area. Initially
though, it was not known exactly where the mutation would lie (if it was
present at all), therefore this gel provided the first indication of the point
mutation. At the bottom of Figure 4.2 the sequence separation is much
greater and easier to read and so in subsequent sequencing of the
mutation the gel was run much further. In order to confirm the mutation
at the 5' end of intron 19, one base 3' to the universally conserved
donor splice site, the complementary strand of genomic DNA was
sequenced, by Dr Steve Wilton. This indicated a "T" normal for
dystrophin changed to a "G" in the BMD patient. This provided
supporting evidence for a mutation in the consensus sequence at the
5' end of lntron 19.

4.4

Discussion

Sequencing of genomic DNA of a subject normal tor dystrophin and
patient G with BMD indicated an "A" to "C" change shown in Figure 4.1.
This indicates a mutation at the 5' end of lntron 19, one base pair 3' to
the universally conserved "G", "T" donor splice site, but in the donor
consensus sequence, necessary for splicing to occur (see Figure 4.3).
Mutations at the donor (5' end of intron) and acceptor (3' end of intron)
splice sites of genes have been shown to produce varied effects in the
formation of mature mANA, including the complete exclusion of exons,
as seen in patient G with BMD.
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Figure 4.2
Sequencing of normal and affected (Patient G) genomic DNA
on a 6% denaturing acrylamide gel. The mutation is evident at
the base after the universally conserved donor splice site "GT"'
'
and results in an "A" to "C" mutation in the affected individual.
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Figure 4.3
Sequencing information derived from the normal and BMD
patients. " • " indicates the site of the mutation, while the arrow
delineates the exon intron boundary.
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5'

lntron 19

l

3'

TGGAACAAGATGGTGAATG GTAATTACACGAGTTGATtTAGATA
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TGGAACAAGATGGTGAATG GTCATTACACGAGTTGATTTAGATA
AG GTAAGT
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BMD sequence

Rees et al (1985), showed in a haemophilia B patient, that the only
significant sequence difference occurred at a donor splice site and
consisted of a single base substitution of a "G" to a "T". Cladaras et al
(1987), showed that an "A" to "G" substitution in the acceptor splice site
of the third intron of a deficient Apo·E gene can cause aberrant
splicing of the third intron. This aberrant splicing led to two mature
mANA's containing either a portion or the entire 3rd lntron of the Apo·E
gene. Cladaros et al (1987), also mentions a similar "A" to "G"
substitution of the second intron of the B globin gene. This mutation,
however only generates a single larger size B globin mRNA that
contains a portion of the second intron.

Mounir et al (1990), showed that a mutation at the JH6 Donor splice
site in the JBL2 gene causes Burkitts Lymphoma. Splicing therefore
occurred at an alternate splice site which was 5' to the normal Donor
splice site. Carstens et al (1991 ), identified two point mutations in the
Ornithine Transcarbamylase (OTC) gene which is an X-linked
recessive gene like DMD and BMD. One patient who had deficiency of
OTC had a "T" to "C" substitution at the Donor splice site of intron 7,
this substitution caused exon 7 to be skipped (see Figure 4.4). This
mutation is similar in effect to the mutation described in our BMD
patient, both are mutations of the donor consensus sequence although
the OTC mutation is at the donor splice site, which results in the
previous exon being skipped. Another patient had an "A" to "T"
substitution at the Acceptor splice site, at the end of lntron 4. This led to
a cryptic 3' Acceptor splice site being formed in exon 5 resulting in a
deletion of 12 bases in the mature mRNA.
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Figure 4.4
Ornithine transcarbamylase gene: A single base mutation, at
the universally conserved donor splice site of intron 7, results
in exon 7 being skipped in the mRNA transcript (Carstens et al,
1991 ). Note that the universally conserved donor splice site is
GU as compared to GT in DNA.
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Takahaski et al (1990), working with the p53 tumor suppressor gene
showed that point mutation at the acceptor and donor splice sites can
both result in the inactivation of p53 tumor suppressor gene. A point
mutation at the acceptor splice site "G" to "C" at the 3' end of intron 3
can generate two forms of mature mRNA. The first form uses a cryptic
acceptor splice site in Exon 4, therefore producing a mRNA with part of
exon 4 incorporated. The second form uses the normal acceptor splice
site at the 3' end of lntron 4. This results in mRNA which has exon 3
connected to exon 5 ie. the complete exclusion of exon 4. The other
mutation noted by Takahashi et al (1990),was a point mutation at a
donor splice site of intron 7, a "G" to a "T". This resulted in the entire
intron 7 sequenctl remaining in the mature mRNA ..
The above examples show that the outcomes of splice site mutations
are varied and result in different mature mRNA transcripts being
produced. It must also be noted that in these cases a mutation of the
donor or acceptor splice sites is significant enough to cause structural
changes in the mature mRNA, which in turn results in phenotypical
changes in protein synthesis. The nested PCR of patient "G" indicated
a deletion of under 100 bp, exon 19 is 88 base pairs long, providing a
candidate area to sequence. This splice site mutation resulted in
alternate splicing of exon 19, with two mRNA transcripts being
produced, one with exon 19 the other without.
The identification of a point mutation in the affected individual by
sequencing, ailthough accurate, is inefficient when analysing all
members of the family for the mutation. Demonstration of fragment
lenglh polymorphism of eDNA, which identified the point mutation
initially, is an extremely difficult procedure and inefficient when
analysing all members of the family for the mutation. The requirement
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.
of a muscle biopsy makes this method highly invasive and impractical
when doing chorionic villi sampling or amniocentisis in order to
provide the family with a pre-natal diagnostic test. Extracting mRNA
from lymphocytes would make this a much more viable method of
characterising the mutation in this family (Roberts et al,1990).
In order for a diagnostic test to be minimally invasive and provide this
family with an accurate pre-natal diagnosis, the test would have to use
genomic DNA extracted from whole blood. This diagnostic test would
also have to distinguish a single base substitution in genomic DNA of
affected males and carrier females. One method considered was
Southern blot analysis. If the point mutation introduced or deleted an
enzyme cutting site, this would lead to a simple and effective Southern
analysis test. Similarly if the mutation introduced or deleted an enzyme
cutting site, then exon 19 with part of intron 19 could be amplified
(PCR) and a restriction digest would identify the affected allele.
Although the site is palindromic no known restriction enzyme cuts at
that particular site, so this approach was not an option.
Another method using restriction enzymes resulted involves the
introduction of a restriction site by polymerase chain reaction. In this
method a mis-match is introduced close to the mutation by a mismatched primer which anneals to the target DNA. The primer which
introduces a mutation into the amplified product, is designed to
introduce a enzyme cutting site, when matched with the mutant allele.
The normal allele would not have the correct base sequence for the
enzyme to cut. This test amplifies and gives a signal for both the
mutant and the affected allele, but only the m'utant allele will be
digested using the appropriate restriction enzyme. This method has
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the advantage of providing a signal but of different sizes depending on
the status of the individual (Schwartz et al, 1991 ). This would be a
viable method of characterising this point mutation, but due to time
constraints it was not tested.
It was decided to use SSCP and the ARMS techniques to characterise
this "A" to "C" point mutation. Although SSCP analysis is generally
used in the identification of point mutations, in this case by having a
point mutation it was possible to optimise the conditions for detecting,
this point mutation and in the process become familiar with the SSCP
technique. The SSCP analysis could be then used to find more point
or minor mutations, in Western Australian dystrophic families (Hayashi,
1991 ). The ARMS method of characterising this

poi~t

mutation,

involved designing primers specific for the mutant and norrna: aJ10Ies
and then

optimising

the

PCR conditions.

These primers,

normal/affected, would only vary at the end base "A" normal and "C" in
the affected primer (Billadeau et al, 1991 ).
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Chapter 5:

SINGLE STRANDED CONFORMATION
POLYMORPHISM

5.1

Introduction

This is a method by which the migration of the single stranded DNA
does not only depend on the number of nucleotides, instead the shape
of the single stranded DNA determines its rate of migration through a
non-denaturing polyacrylamide gel. In normal double stranded DNA
electrophoresis, even on a polyacrylamide gel, it is only possible to
notice small deletions or insertions of DNA. It is not possible to detect
substitutions which do not affect the size of DNA and therefore do not
affect its migration during electrophoresis (Hayashi, 1991 ). Single
stranded DNA under non-denaturing conditions has a stable shape·
conformation, which tends to vary depending on the sequence of the
DNA and the intrastrand reactions. This in turn will cause changes in
electrophoretic migration depending on the shape of DNA (see Figure
5.1) (Hayashi, 1991; Baldwin et al, 1992).
SSCP analysis was carried out on genomic DNA from normal,
carrier and affected individuals in the affected family. Although this
method is conventionally used in the detection of point or minor
mutations, in this case we had already identified a point mutation and
SSCP analysis was done in order to characterise the mutation and
provide an easy screening method for the family. As the mutation
consisted of a single base substitution, fractionation on a
polyacrylamide gel with its high resolution was determined to be the
best method (Orita et al, 1989b). Silver staining of agarose gels
provided a simpler method, but would not have provided the resolution
of the polyacrylamide gel (Bassam et al, 1991). Orita et al (1989a),
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Figure 5.1

SSCP: Migration of double stranded (ds) DNA compared to
single stranded (ss) DNA during electrophoresis. The ds DNA
forms a stable conformation, double helix, and migrates
uniformly dependant on the number of nucleotides. ssDNA
has different conformational forms dependant on the
sequence of the strand and the running conditions. The
complementary strands of DNA when run under appropriate
SSCP conditions should result in two distinct bands.
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noted that most point mutations could be detected when analysing
products less than 500 bases long. As the amplified product was just
under 500 bases long, approximately 460 bases, it was decided to
digest the amplified product with restriction enzymes (frequent cutters)
in order to reduce the fragment size being analysed and therefore
increasing the chance of detecting a polymorphism .

5. 2

Materials and Methods

5 .2.1

Acrylamide stock for SSCP analysis

Volumes of 1OOml of 40% Acrylamide gel stock were made up for use
in SSCP analysis. 1OOmls of 40% acrylamide contains 39g of
Acrylamide, 1g of Bis·Acrylamide and double distilled water to bring
the volume of the solution to 1OOml. This mixture was stirred slowly,
with a magnetic stirrer, until dissolved. 1Og of mixed bed resin was
then added to the beaker containing the acrylamide solution and
stirred slowly for 30 minutes at room temperature. The mixed bed resin
was then filtered from the acrylamide solution, with funnel and filter
paper. DOW was then added to the mixed bed resin, located in the
filter, to bring the volume of acrylamide stock up to 1OOmls. The
acrylamide stock solution was stored at 4°C in a bottle wrapped in
aluminium foil. Since acrylamide is a neurotoxin appropriate safety
precautions were taken whenever it was handled. This included
wearing two sets of gloves, a mask and using the fume hood where
possible.
5.2.2

6% Acrylamlde gel for SSCP analysis

SSCP analysis employs a 6% acrylamide solution and SOmis of the
solution are required to pour Poker Face gel. SOmis of 6% acrylamide
6S

solution contains; 12ml of 40% acrylamide stock, Sml of 1Ox TBE and
60mls of DOW. Then 170ul of TEMED and 170ul of 25% Ammonium
persulphate, which had been stored at 4°C, were also added to the
solution and mixed quickly. The TEMED and 25% Ammonium
persulphate catalysed the polymerisation of acrylamide, turning the
acrylamide into a gel within 5 minutes. The acrylamide solution was
drawn up in a 1OOml syringe and injected between the two glass
plates used in the Poker Face system, making sure not to leave air
bubbles between the plates. A comb, which forms the loading wells,
was then inserted approximately 5 to 1Omm into the gel mix. After the
catalysts had been added, the acrylamide solution was poured quickly
and the comb inserted between the plates, prior to the gel setting.
Once the gel had solidified a moist piece of paper was placed over the
comb and the top end of the gel wrapped in gladwrap to keep in the
moisture. The gel could then be stored for up to a week at room
temperature, prior to being used.
5.2.3

Genomic amplification of exon 19

Primers used in the amplification of exon 19 from genomic DNA were:·
(19F)orward

5' TTCTACCACATCCCATTTTCTTCCA

3'

(19R)everse

5' GATGGCAAAAGTGTTGAGAAAAAGTC

3'

These primers were specified by Abbs et al (1991).
Each PCR reaction consisted of 5ul of 5x buffer, 75 ng/ul primer mix,
0.5 units of Taq Polymerase, 50ng of template genomic DNA, 0.15ul of
dCTP·32 (50uCi Amersham) and the reaction was brought to volume
with DOW and overlaid with one drop of paraffin. Thermal cycling of
samples involved 35 cycles of 94°C for 30 seconds, 55°C tor 1 minute
and 72°C for 2 minutes (the initial denaturation step at 94°C was
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carried out tor 5 minutes). An aliquot of 4ul of the samples was taken
and mixed with 1ul 5x fico II loading buffer. This was run on a 3%
agarose gel at 100 volts for 45 minutes. The gel was then stained with
ethidium bromide and fluoresced under a UV light. This indicated
whether the samples had amplified. If the amplification worked, then
the samples were digested with restriction enzymes.
5.2.4

Digestion of amplified products

After amplification of the genomic DNA it was digested with three
known frequent cutters (Hae Ill, Hha I and Hint 1). The only variation in
digestion conditions for the three enzymes was that Hint I required
buffer"B", while buffer"C' was used for Hae Ill and Hha I (Promega).
The digested reactions consisted of 5ul of 1Ox buffer "C" or "B"
(depending on the enzyme used), 1ul of 0.1 M spermidine, 1ul of
enzyme (Hae Ill, 11 units/ul or Hha I, 12 units/ul or Hint I, 10 units/ul),
0.5ul of 1Omg/ml BSA, 5ul amplified DNA and then brought to volume
with DOW (Promega). The digest reaction was then incubated for 8
hours at 37°C, ethanol precipitated, and resuspended in 1Oul of DOW
and 1Oul of formam ide loading buffer.
5.2.5

Ethanol precipitation

To the DNA sample was added, 3M NaAc (1/10th the volume of the
DNA sample) and then 100% cold ethanol (3 times the volume of the
DNA sample). The sample was then vortexed lightly and left at -80°C
for 2 hours to precipitate. After the DNA had precipitated, the sample
was then spun down at 13650g for 15 minutes and the supernatant
poured off. The DNA pellet was then washed by adding 70% cold
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ethanol (3 times the total volume of original DNA sample) and then the
pellet was spun down for 5 minutes at 15000rpm. The 70% ethanol
was then poured off the DNA pellet, which was then vacuum dried and
resuspend in DOW.

5.2.6

Running 6% polyacrylamide gel for SSCP analysis

5ul of the digested DNA was aliquoted into a fresh tube to be run
under non-denaturing conditions. The rest of the digested DNA was
run under denaturing conditions for SSCP analysis. This involved
heating the sample to 80°C which denatured the DNA. After 10
minutes 2ul of the hot, denatured DNA was loaded onto a 6% non
denaturing polyacrylamide gel (Poker Face) and run in 1x TBE butter.
2ul of the non-denatured DNA was also run on the same gel. The gel
was then run for 8 hours at 400 volts. Prior to loading the samples, the
polyacrylamide gel was pre-run for 30 minutes at 400 volts. The final
step involved fixing, drying and exposing the polyacrylamide gel as
described in 3.6.2.
5.3

Results

Single strand conformation polymorphism analysis of exon 19 using
genomic DNA amplified with primers 19F and 19R, indicated a
polymorphism, therefore providing a means of characterising the point
mutation found in this BMD family. In Figure 5.2 the uncut DNA showed
no polymorphism in samples 1 to 4 both in the normally
electrophoresed and those samples in which SSCP analysis was
performed. It is important to note that single stranded DNA (ssDNA)
migrates much slower than double stranded DNA (dsDNA), during
electrophoresis. Therefore for all digests in Figure 5.2 sample 1 has
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Figure 5.2

SSCP analysis: Autorad showing amplified exon 19 samples

for "1" normal female, 11 2" carrier female, "3" BMD male, "4"
normal male. These samples were run uncut and also cut with
the restriction enzymes Hae Ill, Hha I, Hinf I. pUC 19 marker
digested with Msp I. Sample 1 was loaded twice for each
digest first as double stranded DNA and then as single
stranded DNA.
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been loaded twice. The first time as dsDNA and the second time under
SSCP conditions. This gives an indication of how the double stranded
DNA has migrated in relation to the single stranded (SSCP) DNA.
The Hae Ill digested DNA showed no polymorphism with SSCP
analysis (see Figure 5.2). The DNA digested with Hha I showed a
polymorphism with SSCP analysis; samples 2 and 3 have only two
bands corresponding to carrier female and affected male, samples 1
and 4 have three bands corresponding to normal female and normal
male (see Figure 5.2). In Figure 5.2 Hha I has either cut the amplified
exon 19 at the very end of the amplified product ie. in the primer
sequence or the enzyme has not cut at all. As there is no Hha I
restriction site in the primers (t 9F and 19R), this indicates that Hha I
has not cut exon 19, as any cutting of exon 19 inside the primers would
result in a different sized product compared to the uncut samples (see
Figure 5.2). The only variation between the uncut SSCP and the Hha I
samples was that the Hha I samples were ethanol precipitated where
as the uncut samples were loaded straight from the amplification
reaction. The uncut SSCP samples have salts and MgCI 2 from the
amplification buffer, these would not be present in the Hha I SSCP
samples, this could account for the variation with the Hha I SSCP
samples as seen in Figure 5.2. The Hint I digest of the four
amplification products resulted in at least two products. The smaller
SSCP product can just be seen on Figure 5.2 at the bottom of the
autorad. The second larger product shows a polymorphism using
SSCP analysis. Samples 2 and 3 show two distinct bands indicating
carrier female "2" and affected male "3" while normal female "1" and
normal male "4" have only one band (see Figure 5.2).
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5.4

Discussion

Orita et al (1989b), indicated that a number of factors can influence the
migration of single stranded DNA. For example, the sequence and the
size of the DNA fragments (determined by restriction enzyme), the
temperature, the pH and gel concentration are all important in
determining

rate

of

migration

through

a

non-denaturing

polyacrylamide gel. By varying the conditions of SSCP analysis it is
possible detect most base changes in DNA under 200bp. Optimisation
of the DNA samples 1 to 4 in order to show a polymorphism included
varying the current, the temperature and the running time of gels (data
not shown). Once conditions had been optimised it was possible to
detect a single base change in an amplified product which was just
over 460 bases (see Figure 5.2). This could be due to a single strand
of DNA having more than one stable conformation under a given set of
conditions. This would result in 2 bands from single stranded DNA with
the same sequence as described by Orita et al, (1989b).
Once the conditions for SSCP analysis were optimised it was possible
to determine which individuals had the single base substitution. One
problem was that there was no distinction between carrier female and
affected male, therefore a sex determination test must also be done in
order to provide the family with adequate information to make an
informed decision based on the prenatal tests. This may be a
characteristic of this specific test as Orita et al (1989a), demonstrated
different conditions change the characteristics of migration. It may
therefore be possible to improve on this test, by changing the running
conditions, resulting in a test which is able to distinguish between
affected males and carrier females.
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This test provided a relatively simple method of analysing members of
the family for the point mutation, although time consuming and
requiring the use of 32 P, it must be considered an option for prenatal
diagnostic testing.
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Chapter 6:

AMPLIFICATION REFRACTORY
MUTATION SYSTEM

6.1

Introduction

Amplification refractory mutation system (ARMS). or allele specific
amplification. is a method which makes it possible to amplify DNA
specific to the mutation or specific for the normal allele. This method
uses genomic DNA in polymerase chain reaction (PCR).
Normal and mutant alleles are identified by using two allele specific
oligonucleotide primers. The normal and the affected primer mixes

'

have a common reverse primer while the forward primer varies
between the normal ("T" at the 3' end) and affected primer mixes ("G" at
the 3' end). Fragment amplification occurs only when the allele specific
. primer matches the nucleotide sequence of the template DNA. The
amplified product is detected by agarose gel electrophoresis. followed
by staining with ethidium bromide (Wenham et at 1991; Billadeau et at
1991 ). This method of characterising the point mutation requires
sequence information which was derived from the sequencing of exon

.
19, in, order to design forward primers (l9FA and 19FC) which are
complementary to the 5' end of

intra~ ·19. The primers for the normal

and affected allele vary only at the 3' end base,

which··~aries

from an

"T" for the normal primer to a "G" for the affected primer (see Figure
6.1 ). Once the normal and affected primer mixes were optimised, they
would only anneal and allow amplification when their respective
alleles were present in genomic DNA. Therefore a carrier female
would have the normal and affected primer mixes giving a signal .

.

Affected males would only get a signal from the affected primer mix,
while normal males and females would only get a signal from the
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Figure 6.1

ARMS analysis: a) The BMD primers shown here will only
amplify up the genomic DNA if the mutation which causes
'
, .BMD
in this family is present b) The normal primers will only

amplify, genomic DNA, when the normal allele is present
Reactions (a & b) are specific for their respective alleles and
,only result in amplification when that particular allele is
present

•
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(19FC)
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,3'
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Genomic DNA
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Normal primer

(b)

5' -----------~T==
3'

3'

===r.c----------- 5'
(19R)

Genomic DNA

normal primer mix. The size of the signal for the normal and affected
primer mixes does not vary as the primers amplify the same region of
DNA but are specific for the 3' base change. One of the problems that
could be encountered with this method of characterisation is that of
getting false negatives. How do you know if the negative result is due
to the primer not annealing to the DNA or whether the whole reaction
ha$ not worked? Wenham et al, (1991) suggested having a second set
of primers in the reaction (internal control) with a different sized
product. In this way it is possible to tell if the reaction has worked,
reducing the chance of false negatives. The ARMS method of
characterising a single base mutation was described by Wenham et al
i

(1991) as "simple, reliable and robust and avoiding the use of radiation
or hybridisation with allele specific oligonucle<;>tide probes". This
makes for an ideal diagnostic test!
No single protocol is appropriate for all situations, it is therefore
necessary to optimise each reaction in order to maximise the yield of
the desired product, as opposed to non-specific background bands,
primer dimers and mutations or heterogenicity (Innis et al, 1990).
The magnesium concentration can affect

a· number of factors within a

PCR' reaction including primer annealin'g, product specificity, formation
of pri,;;er dimers and enzymatic activity. Taq polymerase requires free
magnesium on top of that bound by template DNA;· primers and
dNTP's. Therefore PCR reactions should contaln between 0.5 and
2.5 mM MgCI 2. Decreasing the magnesium concentration leads to an
increase in specificity (Innes et al, 1990).
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The temperature and length of time required for primer annealing
depends upon the base composition as well as the length and
concentration of the amplification primers. Annealing temperatures
between 55°C and 72°C generally yield the best results, with
increased annealing temperature leading to greater specificity of
amplification (Innis et al, 1990).
The number of cycles depends on the concentration of target DNA. Too
many cycles can lead to non-specific bacl<nround products, while too
few cycles will give a low product yield. As a rule, however, to go over
40 cycles without getting a signal from a reaction indicates that

'

something is wrong (Innis et al, 1990).
Primer concentrations 0.1 to 0.5uM provide optimal conditions for PCR
reactions. Primer concentrations above 0.5uM can lead

to non-specific

products being produced and also primer dimers annealing to each
other. Primer concentrations below 0.1 uM may lead to insufficiGnt
amplified product being produced (Innis et al, 1990) .
Efficient primers should be 18 to 28 nucleotides long with a 50 to 60%
"G" and "C" composition. The 3' end of primer pairs should not be
complementary, this helps to reduce 'the formation of primer dimer

•

artifacts. It is also important to avoid long stretches of

•
"C'~

and "G" at the

3' end of primers as this may promote mispriming at "G" and "C" rich
sequences and palindromic sequences within primers (a sequence
that reads the same in both directions). In some cases a primer may
not work, due to the secondary structures within the template DNA. In,.
such cases it may be necessary to design another set of primers for
that region (Innis et al, 1990).
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6.2

Materials and Methods

Primers specific to the mutation in axon t 9 and primers for the normal
allele were produced from the sequence data, obtained in chapter 4
(see Table 6.1 ). It was then necessary to optimise the conditions for
each set of primers.

6.2.1

Optimised normal primer

PCR reaction consisted of Sui of Sx buffer (no MgCI in this buffer), 2ul
2

of primer mix 80ng/ul, O.S units of Taq Polymeras·e, 1.7mM of MgC1 2 ,
SOng of genomic DNA and then brought to the volume with DOW and
, overlaid

with one drop of paraffin. Thermal cycling of samples

involved 33 cycles of 94°C for 3 seconds, 56°C for 1 minute and 72°C
for 2 minutes (the initial denaturation step at 94°C was carried out for S
minutes).

6.2.2

Optimised affected primer

PCR reaction was carried out as per normal primer, except the normal
Sx butter was used giving the reaction a MgCI 2 concentration of 2mM
and the annealing temperature was change,d ·from S6°C to S8°C .

.
6.2.3.
,.

Running ARMS products '

•

The products produced by the ARMS amplification were,. run on a 3%
agarose gel at 7S volts for 90 minutes, the gel was then stained with
ethidium bromide and observed under UV light. The product size will
not

vary from "normal" to the "affected" allele. Instead, a signal will only

occ~r

when the affected and normal primers anneal to their exact
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Table 6.1
Primers used in ARMS analysis
Sequence (5' to 3')
PRIMERS USED TO AMPLIFY NORMAL ALLELE
PRIMER"A"
19R
19FA

GATGGCAAAAGTGTTGAGAAAAAGTC
TATCTAAATCAACTCGTGTAATT

PRIMERS USED TO AMPLIFY AFFECTED ALLELE
PRIMER"C"
19R
19FC

GATGGCAAAAGTGTTGAGAAAAAGTC
TATCTAAATCAACTCGTGTAATG

Prim~r 19R was specified by Abbs et a1,(1991).
,.

•

..
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complementary sequence on the template DNA. This means that the
identification of the disease and normal allele is done simply by the
presence or absence of a signal, when doing an amplification,
dependent on which set of primers is being used.

6.3

Results

Optimisation of the ARMS primer was achieved by varying a number of
the PCR conditions. This included varying the number of cycles, the
annealing temperature (data not shown) and. the MgCI2 concentration
(see Figure 6.2). In Figure 6.2 the annealing temperature and the
, number of cycles (PCR) remained constant for both the "normal A"
primer and the "affected C" primer mixes, only the MgCI2 concentration
was

varie~

Figure 6.2 shows that the "affected C" primer worked well

at both 2mM MgCI 2 and 1mM MgCI2 ie. only the BMD male and carrier
female have the affected allele, as expected. The "normal A" primer in
figure 6.2 indicated at a 2mM MgCI 2 concentration that the BMD male
had a normal allele when using "normal A" primer. The BMD male
should not have the normal allele. Reducing the MgCI 2 concentration
to 1mM MgCI2 when using the "normal A" primer resulted in no signal
in anY, of the four samples (see Figure ,6.2). The expected result using
"normal A" primer is that only Normal Male/Female and,Carrier Female
would have this allele. In order to optimise the "normal A" primer the
"

MgCI 2 was then varied between 1 and 2mM, along with the PCR
conditions, until the expected result was obtained as in Figure 6.4.
Polymerase chain reaction provides a very effective way of analysing a
sequence of DNA. The amplification of a sequence of DNA many

.

millions of times can lead to contamination of subsequent PCR
reactions therefore making it necessary to have a negative control in
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Figure 6.2
Optimising ARMS reaction: Varying the MgCI 2 concentration

'

from 1 to 2mM, while maintaining all other PCR conditions.

Primer "A" should only amplify the normal allele, while primer
"C" should only amplify the affected allele. Lambda marker
'

· digested with Pst I.

,.

•
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all PCR reactions and special lab procedures to minimise
contamination. In Figure 6.3, while attempting to optimise the
conditions tor both the "affected C" primer and the "normal A" primer,
the reaction was contaminated resulting in a signal in the "normal A"
primer negative control. It was then necessary to do this amplification
again, making sure not to contaminate the reaction (data not shown).
Once both "normal A" and "affected C" primers were optimised (see
Figure 6.4) it was possible to distinguish a BMD male who only had the
affected allele and a carrier female who had both the affected allele
and the normal allele. Normal males/females only had the normal
i

allele.
Once the conditions had been optimised, all the family members of
patient "G", for which genomic DNA was available were tested in a
. double blind test. This test involved getting genomic DNA from as
many members of patient "G"s family as possible. These samples were
only numbered and by using the ARMS test it was possible .to
determine whether the samples came from normal individuals, carrier
females or affected males (data noy shown).

6.4 '·

Discussion

The A'RMS method of characterising this "A" to "C" poinfmutation in the
family of patient "G" proved to be very simple and effective once the
conditions had been optimised. The nature of PCR reactions make
them susceptible to contamination. It is therefore important to both
follow protocols which minimise the likelihood of contamination (Erlich,
1989) and also to always have a negative control. The double
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Figure, 6.3
Contamination of ARMS reaction: The ·ve control Primer "A"
has given a signal. pUC marker digested with Msp I.
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Figure, 6.4
ARMS roqction optimised for BMD family: Primer "A" amplifies
only when normal allele is present, while primer "C" only
amplifies when the affected allele is present. pUC. marker
digested with Msp I.
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blind ARMS test that was carried out supp01ied previous linkage
analysis done on all family members at this laboratory. These allele
specific oligonucleotide tests therefore provided an extremely easy
and specific meth0d for detecting this mutation.

'

92

Chapter 7:

GENERAL DISCUSSION

Point or minor mutations in the dystrophin gene account for 30% of
DMD and BMD patients (Laing, 1993) In Western Australia this
amounts to twenty families. These families are offered prenatal
diagnostic testing based on linkage analysis. In linkage analysis the
probability of the disease causing allele travelling with a polymorphic
marker is determined. The closer the marker to the mutation, the more
likely it is to travel with the mutation. It is then possible with an
informative marker and an extended family, to determine the
probability of the marker travelling with the mutant allele. Linkage
analysis provides a probability based test which results in a LOD
score, where the LOD score is the logarithm to the base 10 of the odds
of linkage between a marker and the disease gene (Gelehrter and
Collins, 1990, p. 206). A LOD score of +3 means odds of 1000:1 in
favour of linkage, whereas a LOD score of -2 means odds of 100:1
against linkage. In practice LOD scores are calculated for different
distances/number of nucleotides (9) between the marker and the
disease gene, from 0 to 50 centiMorgans. At 50 centiMorgans genes
are considered unlinked.
likelihood (data\8)
Likelihood ratio (9) =
likelihood (data\no linkage)
(Gelehrter and Collins, 1990, p. 205)
The higher/more positive the LOD score the more likely the marker and
the disease gene are linked. Of course if a high LOD score occurs at a
low (9) value the genes are closely linked (Gelehrter and Collins,
1990, p. 206). It has been estimated that in 33% of dystrophic patients,
the mutation first occurs in the affected male. In another 33% of
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dystrophic males the mutation first occurred in their mother and in the
final 33% of dystrophic males the mutation first occurred with their
grandmother (Laing, 1993). Linkage analysis therefore can not always
determine the status of the family members who have a relative
suffering . DMD or BMD as the mutation may be de-novo or the
pedigree not large enough to provide accurate linkage analysis for that
family (Laing, 1993). It is important in these families to locate the actual
mutation to provide them with an accurate prenatal diagnostic test.
This test could also eventually result in the eradication of the mutant
allele in future generations, in these families.
The procedure for locating and characterising point mutations takes
advantage of a number of molecular techniques. PCR provides the
basis for detection .and analysis of these point mutations. This
technique, although very powerful, is subject to contamination by
previously amplified products (see Figure 6.3). It is very important to
use procedures that limit cross contamination of PCR products and the
most effective way of accomplishing this is to use a PCR dedicated
micropipette to load all amplified products. The use of sterile technique
and a PCR dedicated micropipette resulted in only one instance of
contamination.
A point mutation was identified in patient 'G'. This mutation was in the
consensus sequence at the 5' end of intron 19. The base after the
universally conserved donor splice site had changed from "A" to "C".
This point mutation was subsequently characterised by SSCP and
ARMS analysis, providing this family with accurate diagnostic tests.
Patient 'G' has a splice site mutation which results in exon 19 being
spliced out. This is a frameshift mutation and would generally indicate
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DMD phenotype (Monaco et at, 1988). However patient 'G' has BMD
which could be explained by alternate splicing resulting in some lui\
length mRNA transcript which maintains the reading frame. This
alternate splicing is demonstrated by the two PCR products for patient
'G', exons 17·25 in figure 3.4, ana the normal size and the other
smal\er as a result of exon 19 being deleted. Chelly et at (1990)
describes two cases in which BMD patients, had apparent out ol frame
gene deletions, which according to the frameshift hypothesis of
Monaco eta\ (1988), should result in DMD. It was noted, though, that in
these patients alternate splicing had occurred and this restored the
reading frame. Roberts et at (1991) also describes a patients with a
frameshift mutation caused by a deletion of exons 42 and 43 of the
dystrophin gene. Subsequent analysis showed alternate splicing
which resulted in two mRNA transcripts. The minor product results in
exon 44 also being excluded which resulted in the restoration of the
reading frame. This could explain the mild phenotype that was
observed in this patient.
The point mutation found in patient 'G' and the subsequent
characterisation of this point mutation by sequencing, SSCP and al\ele
specific amplification will provide this family with a diagnostic test.
Each of these methods have their own limitations. For example
sequencing gels can be hard to read (cross·banding) and SSCP and
al\ele specific amplifications can be hard to optimise. A diagnostic test
would be of considerable importance should a carrier ~emale ever
decide to have a child. The allele specific amplification test devised for
this family was the easiest test to perform and interpret, once the
conditions had been optimised. Yet SSCP analysis may be used as a
confirmatory test in prenatal diagnosis. Prenatal diagnostic tests on
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family members of patient 'G' previously performed by this laboratory
consisted of linkage analysis. The limitations of this procedure have
already been noted. The allele specific amplification test detects the
actual point mutation reducing the chance of mis-diagnosis.
The identification and characterisation of this one point mutation in
patient 'G' is of no direct consequence to the other families throughout
Western Australia who also have a small disease causing mutation in
the dystrophin gene. The successful identification of this point mutation
could hold some hope for them that, in the not to distant future, a
similar feat may .be achieved for them. However, in the meantime these
families still rely on linkage analysis for prenatal diagnosis, which in
many cases is uninformative and until such time that their specific
mutations are characterised, the accuracy of their diagnoses can not
be assured.
The mutation in patient 'G' resulted in a complete exon being skipped
most of the time. This mutation only becomes obvious when mRNA
was converted to eDNA and then the eDNA amplified. The major
problem with this technique was the mRNA for dystrophin is mainly
present in muscle,

a tissue that was/is often hard to obtain from

patients with BMD or DMD (Chelly et al, 1991 ). When it is obtained it is
often fibrous and the muscle cells have degenerated (Kaido et al,
1991 ). Chelly et al (1991) noted that illegitimate transcription occurs in
all cell types and that the illegitimate transcripts are a bona fide version
of tissue specific mRNA. Chelly et al (1991) also showed it was
possible to extract from non-specific cell types (lymphocytes),
illegitimate mRNA which is tissue specific for, say, muscle cells.
Although the presence of this illegitimate transcript can be up to 25
000 times less in such non-specific cells (Chelly et al 1988), this
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method of mRNA extraction from non-specific cells, should provide a
much more practical and less traumatic means of obtaining mRNA
from dystrophic patients in the future.
SSCP provides a means of characterising a mutation (which was done
with patient 'G') as well as a means of locating point mutations (Orita et
al, 1989b). Another method, mis-match analysis, encourages
heteroduplexes to be formed between normal and affected DNA. The
resultant mis-matches are incubated with osmium tetroxide and then
incubated with piperidine to cleave the DNA at the mis-match. End
labelling of one primer wiil indicate where the mutation lies. (Cotton et
al, 1988; Roberts et a\, 1989). This may provide a much more effective
way of looking at the amplified eDNA transcript of the dystrophic
patients with point' mutations. Roberts et al (1989), indicates that all
types of mutations may be identified using the mis-match cleavage
method. However the mis-match cleavage method does use highly
toxic chemicals and this is a major disadvantage of the technique.
Future research in identifying point mutations in the dystrophin gene
and any other localised gene would need to consider the techniques
of extracting mRNA from non-specific cells and the mis-match
cleavage technique. It is hoped that by using these new techniques,
the trauma to the patient will be reduced as will the time needed to
characterise each point or minor mutation. These procedures of
locating and then working up a diagnostic test specific for the mutation,
will become common laboratory practices in the future. A!\hough time
consuming at present, locating these point mutations provides thes•3
families with the confidence to make an informed decision about
whether or not to have more children.
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TABLE

A)

BUFFERS AND ETHIDIUM BROMIDE

ELECTROPHORESIS BUFFERS
BUFFER

WORKING
SOLUTION

CONCENTRATED STOCK
SOLUTION (per Litre)

Tris~acetate

1x: 0.04M Trls-acetate

sox: 242g "fris base
57.1 ml glacial acetic acid

(TAE)

0.001M EDTA

100rr.l 0.5M EDTA (pH 8.0)
Trls-borate

(TBE)

0.5x: 0.045M Tris-borate
0.001M EDTA

5x: 54g Tris base

27 .Sg boric acid
20ml 0.5M EDTA (pH 8.0)

GEL LOADIWl BUFFERS
BUFFER TYPE

BUFFER

Ficoll
(6x)

0.25% bromophenol blue
0.25% xylene cyanol FF

STORAGE
TEMPERATURE

room temp

15% Ficoll (Type 400; Pharmacia)

in water
Formamlde
(1X)

98% deionized formamide
10mM EDTA (pH 8.0)

0.025% xylene cyanol FF
0.025% bromophenol blue

ETHIDIUM BROMIDE
STOCK CONCENTRATION

STAINING CONCENTRATION

10mg/ml
(1g of Elhidium Bromide
in 100ml of H 0)
2

O.Sug/ml

(Sambrook et al, 1989)
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TABLE

B)

ABBREVIATIONS

AMV·RTase Avian myeloblastosis virus reverse

transcriptase
ARMS Amplification refractory mutation system
APS Ammonium persulphate
BMD Backer muscular dystrophy

bp Base pairs
eDNA Complementary deoxyribonucleic acid
ddATP Dideoxyadenine triphosphate

'

ddCTP Dideoxycytosine triphosphate
ddGTP Dideoxyguanine triphosphate
ddNTP Dideoxynucleotide triphosphate

, , ddTTP Dideoxythymine triphosphate
DOW Double distilled water
DMD Duchenne muscular dystrophy
DNA Deoxyribonucleic acid
dNTP Deoxynucleotlde triphosphate
dsDNA Double stranded deoxyribonu9leic acid

kb Kilobases

'>1. ••

mRNA Messenger ribonucleic acid
PCR Polymerase chain reaction
rRNA Ribosomal ribonucleic acid
RNA Ribonucleic acid
snRNA Small nuclear ribonucleic aGid
SSCP Single strand conformation polymorphism
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ssDNA Single stranded deoxyribonucleic acid
T AE Tris-acetate
TBE Tris-borate
TEMED N,N,N',N',-Tetramethyl~thylenediamine
!RNA Transfer ribonucleic acid

I

UV Ultra-violet
V Volts
SDS Sodium dodecyl sulfate
EDTA Disodium ethylenediaminetetraacetate

'

•
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